The Filtrate:

Joel Topf

Swapnil Hiremath

Josh Waitzman

Jordy Cohen

Special Guest:

Sean Barbour. Clinical Associate Professor, Division of Nephrology, University of British Columbia Chair, BC Glomerulonephritis Committee and Network, BC Renal

Editor:

Joel Topf

Show Notes:

NephJC Summary of TESTING: Re-TESTING Steroids for IgA Nephropathy (have you ever noticed how good the titles for the NephJC summaries are?)

TESTING in JAMA

STOP-IgA NephJC Summary: Don't just do something, stand there. Another great title, this one from from a long time ago.

The British Columbia GN network really owes its existence to TESTING: An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework (PubMed)

Dunning–Kruger effect Wikipedia

Prior Art for steroids in IgA nephropathy:

Italian study: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy

Another, earlier, Italian study: Corticosteroids in IgA nephropathy: a randomised controlled trial

Chinese study: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

Original TESTING publication from 2017, also in JAMA. Oh, and we covered that in NephJC too, IgA Nephropathy: Testing Steroids Again.

NephJC also talked about Sean Barbour’s risk score for IgA Nephropathy: Summary | Freely Filtered Podcast episode 5

A Controlled Trial of Fish Oil in IgA Nephropathy in the NEJM!

Stevens-Johnson Syndrome. “When to see a doctor Stevens-Johnson syndrome requires immediate medical attention. Seek emergency medical care if you experience signs and symptoms of this condition.”

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency (PubMed)

Adaptive Trials in NephMadness 2016 with Selection Committee Member, Perry Wilson!

Treif

Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis

The MEST score provides earlier risk prediction in lgA nephropathy

DAPA-IgA: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Swap and Josh fight about SGLT2i in IgA Nephropathy

Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study (PubMed)

FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. FDA has granted accelerated approval for  budesonide delayed release capsules to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. It has not been established whether budesonide delayed release capsules slow kidney function decline in patients with IgA nephropathy.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial (Lancet)

Omicron in Ontario.

Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD by Swap

Star Trek: Strange New Worlds

Origins of Renal Physiology: Fellows 2022

Medical Students: Kidney TREKS

Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy (Kidney International)

The Triple Crown in Virginia